Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Neubase Therapeutics Inc
Healthcare
P/NCAV
0.18x
Ticker
NBSE
Exchange
NASDAQ
Country
United States
Close
0.42 $
Mkt Cap
694965 $
EV
-11.9M $
NCAV Burn Rate
74.5%
Current Ratio
2.87
Debt/Equity
0.0
EV/REV
N/Ax
EV/EBIT
2.6x
EV/FCF
2.1x
Dilution
45.8% p.A
Total Net Income
-195.0M $
Cheapness
94.0%
NeuBase Therapeutics, Inc. is a preclinical-stage biotechnology company. It is developing a modular peptide-nucleic acid (PNA) antisense oligo (PATrOL) platform to address genetic diseases, with a single, cohesive approach. The Company’s programs are NT-0100 in HD, NT-0200 in myotonic dystrophy type 1 (DM1) and NT-0300 in KRAS-driven cancers. The NT-0100 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the HD DNA or RNA. The NT-0200 program is a PATrOL-enabled therapeutic program being developed to target the mutant expansion in the DM1 disease RNA. The NT-0300 program is a PATrOL-enabled therapeutic program being developed to target the mutated KRAS gene. It uses its platform to address diseases which have a genetic source, with an initial focus on gene silencing in DM1, Huntington’s disease (HD), and oncology and in gene editing applications. It also focused on identifying and evaluating multiple indications for potential development.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average